Core Technology PICT
Bottlenecks in Peptide Drug Development
It has a short half-life and is not easily administered orally.
1. Prone to enzymatic degradation, oxidation, and hydrolysis; exhibits poor stability.
2. High renal clearance
3. Prone to aggregation and precipitation
4. Low cell membrane permeability
- Peptide Synthesis Chemistry
- Peptide Medicinal Chemistry
- Peptide formulations and delivery optimization
- Structural biology, computational chemistry
1. Cyclic structure
2. Amino-terminal methylation
3. Introduction of non-natural or D‑configured amino acids
4. Fatty acidylation, PEGylation, and fusion proteins
5. Optimization of drug delivery systems: liposomes, nanoparticles, microspheres, etc.
There is a scarcity of sources for peptide-based bioactive molecules.
1. Endogenous peptides/natural bioactive peptides
2. Chemically Synthesized Peptides
3. Phage-display peptide library/mRNA-display peptide library/DNA-encoded peptide library/virtual peptide library
- Limited quantity; difficult to isolate, identify, and synthesize.
- Small storage capacity and insufficient diversity; high costs and time-consuming.
- Compound library; large library capacity; screening methods with limited target scope; high false-positive and false-negative rates.
PICT technology
Comparative Analysis of Similar Technologies
PepLib (China)
PICT
1、Library size: 0.5x109
2、Quantitative peptide determination with fewer false positives/negatives
3、One peptide per well, suitable for HTS
4、Active molecular sequences are known
5、Suitable for a wide range of targets
6、Versatile screening methods: suitable for molecular, cellular, and animal-level screening
Bicycle (UK)
Phage Display
1、Library size: 10⁹-¹¹
2、Variable peptide quantities with higher chance of false positives/negatives
3、Active molecular sequences require gene sequencing
4、Limited to water-soluble targets: generally, not suitable for membrane protein targets
5、Screening limited to molecular-level binding assays
6、Double-loop structures with good stability
PeptiDream (Japan)
mRNA Display
1、Library size: 10⁹-¹¹
2、Variable peptide quantities with higher false positives/negatives
3、Mixture format, not suitable for HTS
4、Active molecular sequences require gene sequencing
5、Screening limited to molecular-level binding assays
6、Suitable only for water-soluble targets: generally, not suitable for membrane proteins
7、Can incorporate non-natural amino acids
The process of discovering bioactive molecules using a comprehensive peptide library.
The Process of Innovative Peptide Drug Development